Eupatin, a Flavonoid, Inhibits Coronavirus 3CL Protease and Replication

The coronavirus disease 2019 (COVID-19) pandemic has caused more than six million deaths worldwide since 2019. Although vaccines are available, novel variants of coronavirus are expected to appear continuously, and there is a need for a more effective remedy for coronavirus disease. In this report, we isolated eupatin from Inula japonica flowers and showed that it inhibits the coronavirus 3 chymotrypsin-like (3CL) protease as well as viral replication. We showed that eupatin treatment inhibits SARS-CoV-2 3CL-protease, and computational modeling demonstrated that it interacts with key residues of 3CL-protease. Further, the treatment decreased the number of plaques formed by human coronavirus OC43 (HCoV-OC43) infection and decreased viral protein and RNA levels in the media. These results indicate that eupatin inhibits coronavirus replication.

Natural products have been used medicinally worldwide since ancient times. They contain several secondary metabolites with the potential to prevent or treat various human diseases [6,7]. Plant-derived secondary metabolites include alkaloids, polyphenols, flavonoids, terpenoids, and phytosterols [8]. Flavonoids are phenyl-substituted chromones with a C 6 -C 3 -C 6 carbon skeleton consisting of two benzene rings (rings A and B) linked with a three-carbon heterocyclic ring (ring C) [9]. They are widespread in the plant kingdom, and more than 9000 flavonoids have been identified as secondary metabolites in plants [10]. Flavonoids are of great interest in medicine due to their diverse pharmacological properties, including antioxidant, anti-inflammatory, analgesic, anticancer, antibacterial, antifungal, and antiviral activities [11].
While searching for effective SARS-CoV-2 3CL-protease and coronavirus inhibitors from natural sources, we isolated and identified eupatin as the main active compound in the flower extract of Inula japonica Linnaeus (Asteraceae) [12]. A recent report demonstrated that eupatin exerts anti-inflammatory effects by suppressing the expression of phospho-p65, inducible nitric oxide synthase, and cyclooxygenase-2 [13]. In this study, we demonstrated that eupatin inhibits the activity of SARS-CoV-2 3CL-protease, and computational models support the hypothesis that it interacts with 3CL-protease. We used the human coronavirus OC43 (HCoV-OC43) model coronavirus system [14] and demonstrated that eupatin treatment inhibits coronavirus replication of coronavirus.

Isolation and Identification of Eupatin
Chromatographic separation of the ethanol extract of I. japonica flowers led to the isolation of an amorphous yellow powder with the molecular formula C 18 Figure S3). The signals at δ H 3.90, 3.86, and 3.80 (each 3H, s) were assigned to the methoxy groups at C-6, C-7, and C-4 , respectively. The 13 C-NMR spectrum showed that this compound contained 18 carbons, of which 15 carbon signals were assigned to the 3-O-substituted flavonol structure, and three carbon signals (δ C 59.7, 56.3, and 55.7) were assigned to three methoxy groups substituted in the flavonol structure ( Figure S3). Finally, this compound was identified as eupatin by comparing its spectral data with those reported in the literature [6] ( Figure 1A). demonstrated that eupatin exerts anti-inflammatory effects by suppressing the expression of phospho-p65, inducible nitric oxide synthase, and cyclooxygenase-2 [13]. In this study, we demonstrated that eupatin inhibits the activity of SARS-CoV-2 3CL-protease, and computational models support the hypothesis that it interacts with 3CL-protease. We used the human coronavirus OC43 (HCoV-OC43) model coronavirus system [14] and demonstrated that eupatin treatment inhibits coronavirus replication of coronavirus.  Figure S3). The signals at δH 3.90, 3.86, and 3.80 (each 3H, s) were assigned to the methoxy groups at C-6, C-7, and C-4′, respectively. The 13 C-NMR spectrum showed that this compound contained 18 carbons, of which 15 carbon signals were assigned to the 3-Osubstituted flavonol structure, and three carbon signals (δC 59.7, 56.3, and 55.7) were assigned to three methoxy groups substituted in the flavonol structure ( Figure S3). Finally, this compound was identified as eupatin by comparing its spectral data with those reported in the literature [6] ( Figure 1A).

The Inhibitory Activity of Eupatin on SARS-CoV-2 3CL-Protease
The enzyme inhibitory activity was evaluated in vitro prior to the coronavirus inhibition experiment. Eupatin inhibited the catalytic reaction of the 3CL-protease with the substrate in a concentration-dependent manner at 12.5-100 µM concentration. Based on this, the calculated IC 50 value of the compound was 34.9 ± 1.7 µM ( Figure 1B). The binding between the compound and enzyme was analyzed using enzyme kinetics. As indicated in Figure 1C and Table 1, this inhibitor was confirmed to be binding to the active site of 3CL-protease as a competitive inhibitor, with k i values of 30.0 µM ( Figure 1D).

The Prediction of Binding Pose between Eupatin and 3CL-Protease
This study visualized the binding of eupatin in the active site of the 3CL-protease based on computational chemistry ( Figure 1E). The autodock program tracked their optimal bonding energy, and a most stable value of −7.47 kcal/mol autodock score was calculated ( Table 1). The 5-hydroxyl group of the inhibitor maintained a hydrogen bond at a 2.91 Å distance with Cys145 ( Figure 1F, Table 1). Moreover, the 3 -hydroxyl group formed four hydrogen bonds at 2.98, 2.68, 2.79, and 2.95 Å distance with Arg188, Thr190, and Gln192, respectively.

Molecular Dynamics Study of Eupatin with SARS-CoV-2 3CL-Protease
To analyze the detailed interaction between the ligand and receptor, molecular dynamics studies were performed on the complex with molecular docking. They showed a stable and fluid motion while maintaining −2.3 × 10 6 kJ/mol potential energy for 30 ns (Figure 2A,B). The protein-based root-mean-square derivation (RMSD) was below 0.5 nm, according to the protein movement over time compared to the initial protein ( Figure 2C). In root-mean square-fluctuations (RMSF), some amino residues also had motions of 0.3-0.5 nm ( Figure 2D). They mainly formed 2-4 hydrogen bonds, occasionally 0 and 5-7 ( Figure 2E). Analyzing these simulation times at 3 ns intervals confirmed that four amino residues (His41, Glu166, Thr190, and Gln192) form major hydrogen bonds. His41 maintained a distance of~4 Å to the 4-keton of eupatin for 30 ns. Glu166 and Gln192 maintained a distance of~3 Å from the 1-ether and 3 -hydroxyl groups, respectively. Notably, Thr190 formed two hydrogen bonds with the 3 -hydroxyl group and maintained~2.5 a distance of 0 to 28 ns.

Eupatin-Treatment-Reduced Coronavirus Replication
Since eupatin inhibits 3CL protease activity, we hypothesized that eupatin reduces human coronavirus replication. A plaque formation assay was used to examine the effect of eupatin on coronavirus replication. RD cells were treated with mock or eupatin and infected with the indicated dilutions of HCoV-OC43-infected cell media. Eupatin treatment decreased plaque formation in RD cells in a dose-dependent manner ( Figure 3A,B). In addition, we examined the cytotoxicity of eupatin in RD cells. RD cells were treated with the indicated concentrations of eupatin for 24 h, and cell viability was measured. While a high-dose eupatin (>10 µM) treatment showed cytotoxicity, a lower dose did not significantly affect the viability of RD cells ( Figure 3C).

Eupatin Inhibits Coronavirus Protein Expression and Replication
As eupatin treatment reduced plaque formation, we examined the expression levels of coronavirus proteins. RD cells were treated with mock or eupatin and infected with HCoV-OC43. Eupatin treatment did not change the viral protein expression in the infected cells; however, it dramatically reduced the level of HCoV-OC43 protein in the conditioned media ( Figure 4A,B). Since the coronavirus protein in the conditioned media was derived from coronavirus particles, these results indicated that eupatin treatment decreases the level of coronavirus particles in the media.

Eupatin-Treatment-Reduced Coronavirus Replication
Since eupatin inhibits 3CL protease activity, we hypothesized that eupatin reduces human coronavirus replication. A plaque formation assay was used to examine the effect of eupatin on coronavirus replication. RD cells were treated with mock or eupatin and infected with the indicated dilutions of HCoV-OC43-infected cell media. Eupatin treatment decreased plaque formation in RD cells in a dose-dependent manner ( Figure  3A,B). In addition, we examined the cytotoxicity of eupatin in RD cells. RD cells were treated with the indicated concentrations of eupatin for 24 h, and cell viability was measured. While a high-dose eupatin (>10 μM) treatment showed cytotoxicity, a lower dose did not significantly affect the viability of RD cells ( Figure 3C).

Eupatin Inhibits Coronavirus Protein Expression and Replication
As eupatin treatment reduced plaque formation, we examined the expression levels of coronavirus proteins. RD cells were treated with mock or eupatin and infected with HCoV-OC43. Eupatin treatment did not change the viral protein expression in the infected cells; however, it dramatically reduced the level of HCoV-OC43 protein in the conditioned media ( Figure 4A,B). Since the coronavirus protein in the conditioned media was derived  Then, we examined the expression of HCoV-OC43 RNA in infected cells and media using quantitative RT-PCR. RD cells were treated with mock or eupatin and infected with HCoV-OC43. We evaluated the level of coronavirus RNA in the conditioned media 72 h after infection. The HCoV-OC43 M, N, and RNA-dependent RNA polymerase (RDRP) genes were used to evaluate the level of coronavirus RNA. Similar to protein expression, eupatin treatment did not affect the level of coronavirus RNA in infected cells. However, eupatin treatment effectively decreased the level of coronavirus RNA (M, N, and RdRp genes) in the conditioned media ( Figure 4C). These results indicated that eupatin treatment decreases the level of coronavirus in the media.

Discussion
Humans have used natural products for millennia to treat diseases and health disorders [15]. Some medicinal plants are useful antiviral agents [16]. Secondary metabolites derived from these medicinal plants can play an essential role in antiviral drug discovery by providing lead scaffolds that can be optimized by synthetic and medicinal chemists. I. britannica is one of the most commonly used plant species in traditional Chinese medicine for treating digestive disorders, bronchitis, and various  Figure 4C). These results indicated that eupatin treatment decreases the level of coronavirus in the media.

Discussion
Humans have used natural products for millennia to treat diseases and health disorders [15]. Some medicinal plants are useful antiviral agents [16]. Secondary metabolites derived from these medicinal plants can play an essential role in antiviral drug discovery by providing lead scaffolds that can be optimized by synthetic and medicinal chemists. I. britannica is one of the most commonly used plant species in traditional Chinese medicine for treating digestive disorders, bronchitis, and various types of inflammation [17,18]. The flowers of this plant contain various secondary metabolites such as steroids, terpenoids (sesquiterpenes, diterpenes, and triterpenoids), phenolics, and flavonoids [17]. Flavonoids are frequently reported as major active ingredients that exhibit enzyme inhibitory, antioxidant, and cytotoxic activities [17]. Structurally, eupatin contains a 3-O-substituted flavonol skeleton with three methoxy groups. It has been reported to possess anti-inflammatory and acetylcholinesterase-inhibitory effects [13,19].
In a recent report, we confirmed the inhibitory effects on SARS-CoV-2 3CL-protease and HCoV-OC43 of hispidulin, patuletin, and nepetin from I. britannica flowers [20]. Moreover, recent computer simulation studies reported that eupatin could bind to 3CL-protease and ACE2 [21]. Eupatin, a flavonoid isolated from the flower extract of I. japonica, exhibited considerable 3CL-protease inhibitory activity. Eupatin stably fits into the active site as a competitive inhibitor. The molecular simulation revealed the key amino acids for this inhibition as His41, Glu166, Thr190, and Gln192. We showed that eupatin treatment resulted in decreased coronavirus replication. Notably, eupatin treatment did not significantly change the levels of coronavirus protein and RNA in infected cells; however, eupatin treatment decreased the levels of both protein and RNA in the media. As the viral protein and RNA in the media are from viral particles, these results suggest that eupatin inhibits the release of coronavirus from the cells. The total amounts of viral protein and RNA (media and cells) were reduced by eupatin treatment. Oseltamivir (Tamiflu) also inhibits the spread of the influenza virus by inhibiting neuraminidase, and further studies are required to elucidate the detailed mechanism of eupatin [22].
High concentrations of single compounds isolated from plants often result in cytotoxicity. Similarly, we found that a high concentration of eupatin (≥10 µM) resulted in significant cytotoxicity; however, lower concentrations (0.5-5 µM) inhibit coronavirus replication significantly. Therefore, eupatin concentration should be considered in further experiments to prevent cytotoxicity. Alternatively, the development of derivative compounds with low cytotoxicity is desirable to improve their efficacy.
In this report, we did not use SARS-CoV-2 due to the stringency of regulations. However, HCoV-OC43 and SARS-CoV-2 belong to the beta coronavirus family and share many biological characteristics. Therefore, the knowledge obtained from eupatin and HCoV-OC43 will be helpful in the development of novel drugs for coronaviruses.